Cargando…
Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
A 56-week randomized controlled trial was conducted to evaluate safety and efficacy of a controlled-release combination of phentermine and topiramate (PHEN/TPM CR) for weight loss (WL) and metabolic improvements. Men and women with class II and III obesity (BMI ≥ 35 kg/m(2)) were randomized to place...
Autores principales: | Allison, David B., Gadde, Kishore M., Garvey, William Timothy, Peterson, Craig A., Schwiers, Michael L., Najarian, Thomas, Tam, Peter Y., Troupin, Barbara, Day, Wesley W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3270297/ https://www.ncbi.nlm.nih.gov/pubmed/22051941 http://dx.doi.org/10.1038/oby.2011.330 |
Ejemplares similares
-
Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release
por: Garvey, W. Timothy, et al.
Publicado: (2014) -
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study(1)(2)(3)
por: Garvey, W Timothy, et al.
Publicado: (2012) -
Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity
por: Shin, Jin Hee, et al.
Publicado: (2013) -
Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity
por: Jordan, Jens, et al.
Publicado: (2014) -
Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate
por: Sweeting, Arianne N, et al.
Publicado: (2014)